From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history

Zofin or Organicell Flow is an unapproved treatment that has been used on a number of patients severely ill with long-lasting COVID-19 symptoms under a compassionate use authorization.[1][2] Zofin is a biological product derived from the human amniotic fluid (HAF) donated from the births of healthy, newborn babies; it is administered by intravenous infusion.

Zofin is produced by the company Organicell which states that it "contains over 300 growth factors, cytokines, and chemokines as well as other extracellular vesicles/nanoparticles derived from amniotic stem and epithelial cells" including the proteins CD63, CD81, and CD9 in addition to high expression of CD133.[1]

Theory[edit | edit source]

According to Organicell, pro-inflammatory cytokines believed to be targeted by Zofin include tumor necrosis factor (TNF), IL-6, and IL-8, and published research states that targeting these may "reduce the severity of symptoms associated with elevated immune response".[1]

Theory[edit | edit source]

Evidence[edit | edit source]

Clinicians[edit | edit source]

Risks and safety[edit | edit source]

Zofin has not yet been approved for use and clinical trials remain ongoing.[3]

Risks, side effects and safety are largely unknown.

Costs and availability[edit | edit source]

Zofin is not yet an approved drug and availability is limited to special authorizations.

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]